WuXi STA plant gets FDA nod for 2 APIs, passing its first inspection

WuXi has passed its first FDA inspection at its API plant in Changzhou, China. (WuXi)

The solid-dose API operation of China’s WuXi had its first visit by FDA inspectors at a new plant in Changzhou, China, and the company says it aced it.

The facility won FDA approval for two APIs during a preapproval inspection that was concluded with no observations, WuXi’s SynTheAll Pharmaceutical (STA) said Monday.  

“The Changzhou facility passing its first FDA inspection, with no observations, even with no written or verbal recommendations, is yet further proof of our commitment to the highest possible quality standards,” WuXi STA CEO Minzhang Chen said in a statement.


Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

The CDMO has previously passed FDA inspections at its production sites in Shanghai, Jinshan and Shanghai, Waigaoqiao.

RELATED: A year in, WuXi's STA bulks up its API R&D engineering at China site

The site in Changzhou opened in 2016 and currently has three plants and more than 1,000 employees, including 200 scientists, the company said. It is being built in stages but when all is said and done, it will include more than 500 scientists and 1,500 cubic meters of reactor volume. It currently has more than five dozen APIs and/or intermediates under development and one NCE in commercial production.

RELATED: China's WuXi Biologics to build biologics plant in Ireland that will employ 400

STA is not part of WuXi's biologics operations, which the company also is expanding. Last month, WuXi Biologics announced plans to invest €325 million ($392 million) to build a biologics facility in Dundalk, Ireland, and create a campus of 26 hectares (2.8 million square feet). The project is its first outside of China where it currently boasts the largest biologics plant build on single-use bioreactor technology.

Suggested Articles

AZ and Daiichi reported "impressive" data for DS-8201. J&J and Legend's CAR-T showed promise in multiple myeloma. South Korea jailed Samsung…

Having only just completed an expansion in Illinois, PCI Pharma Services will now expand its solid dose facility in Wales in the U.K.

With a green light in lung cancer, AstraZeneca's Imfinzi has become the first PD-L1 drug approved in China, ahead of Roche's Tecentriq.